ImmuPharma (LON:IMM)‘s stock had its “buy” rating reiterated by analysts at Northland Securities in a research report issued on Thursday. They currently have a GBX 181 ($2.45) price objective on the stock. Northland Securities’ price target suggests a potential upside of 12.42% from the stock’s current price.
IMM has been the topic of a number of other reports. FinnCap began coverage on ImmuPharma in a report on Tuesday, December 12th. They issued a “buy” rating and a GBX 237 ($3.21) target price on the stock. Northland Capital Partners reaffirmed a “buy” rating and issued a GBX 181 ($2.45) target price on shares of ImmuPharma in a report on Thursday, September 21st.
Shares of ImmuPharma (IMM) traded up GBX 6 ($0.08) during trading on Thursday, reaching GBX 161 ($2.18). The company had a trading volume of 1,518,983 shares, compared to its average volume of 471,372. ImmuPharma has a one year low of GBX 44 ($0.60) and a one year high of GBX 193.74 ($2.63). The company has a market cap of $198.37 and a PE ratio of -4,025.00.
ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.